Nicola Storey

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

Quality of life after postmastectomy radiotherapy in patients with intermediate-risk breast cancer (SUPREMO): 2-year follow-up results of a randomised controlled trial

Galina Velikova, Linda Williams, Sarah Willis et al. · The Lancet Oncology · 2018 · 80 citations · Full text

Quality Of Life, Surgical Oncology, Radiation Therapy +11

Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial

Madeleine King, Emma Link, Timothy J. Whelan et al. · The Lancet Oncology · 2020 · 49 citations

Surgical Oncology, Breast Oncology, Health Sciences +10

STUDIES IN THE CHEMOTHERAPY OF TUBERCULOSIS: PART V. THIOSEMICARBAZONES AND RELATED COMPOUNDS

Eric Hoggarth, Anandi Martin, Nicola Storey et al. · British Journal of Pharmacology and Chemotherapy · 1949 · 26 citations · Full text

Pulmonary Tuberculosis, Health Sciences, Medicine +9